Antidepressants versus placebo for depression in primary care

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Arroll, Bruce ^a   Elley, C Raina ^a   Fishman, Tana ^a   Goodyear Smith, Felicity A ^a   Kenealy, Tim ^a   Blashki, Grant ^b   Kerse, Ngaire ^a   MacGillivray, Stephen ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOBARBITAL; ANTIDEPRESSANT AGENT; CITALOPRAM; DIAZEPAM; DOSULEPIN; ESCITALOPRAM; HYPERICUM EXTRACT; IMIPRAMINE; MIANSERIN; NITRAZEPAM; OXAZEPAM; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; VENLAFAXINE;

AGED; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HEART PALPITATION; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PERIPHERAL NEUROPATHY; PRIMARY MEDICAL CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; STOMACH PAIN; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 70049091006     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007954     Document Type: Review

References (69)

1. * Barge-Schaapveld DQ, Nicholson NA. Effects of antidepressant treatment on the quality of daily life: an experience sampling study. Journal of Clinical Psychiatry 2002;63(6):477-485
2. Blashki TG, Mowbray R, Davies B. Controlled trials of amitriptyline in general practice. BMJ 1971;1(5741):133-138
3. Blashki TG, Mowbray R, Davies B. Controlled trials of amitriptyline in general practice. BMJ 1971;1(5741):133-138
4. Brink CW, van der Krogt JP, Dunbar GC, Behagel LH. A controlled clinical trial of mianserin and placebo in the treatment of depression in general practice. Tijdschrift voor therapie, geneesmiddel, en onderzoek 1984;9(10):513-517 (Pubitemid 15195404)
5. Doogan DP, Langdon CJ. A double-blind, placebo controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. International Clinical Psychopharmacology 1994;9(2):95-100. (Pubitemid 24160564)
6. Feighner JP, Brauzer B, Gelenberg AJ, Gomez E, Kiev A, Kurland ML, et al.A placebo-controlled multicenter trial of limbitrol versus its components amitriptyline and chlordiazepoxide. Psychopharmacology 1979;61(2):217-225
7. Hollyman JA, Freeling P, Paykel ES, Bhat A, Sedgwick P. Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. Journal of the Royal College of General Practitioners 1988;38(314):393-397 (Pubitemid 18213984)
8. Lecrubier Y, Bourin M, Moon CA, Schifano F, Blanchard C, Danjou P, et al.Efficacy of venlafaxine in depressive illness. Acta psychiatrica Scandinavica 1997;95(6):485-493
9. Lepola U, Loft H, Reines EH. Escitalopram is efficacious and well tolerated for the treatment of depression in primary care. Abstract: Annual meeting the American Medical Association. New Orleans. 2001.
10. Lepola UM, Loft H, Reines EH. Escitalopram (10-20mg/day) is effective and well tolerated in a placebo controlled study in depression in primary care. International Journal of Clinical Psychopharmacology 2003;18(4):211-217 (Pubitemid 36871872)
11. Lepola U, Loft H, Reines EH. Escitalopram is efficacious and well tolerated for the treatment of depression in primary care. Abstract: Annual meeting the American Medical Association. New Orleans. 2001.
12. Lepola UM, Loft H, Reines EH. Escitalopram (10-20mg/day) is effective and well tolerated in a placebo controlled study in depression in primary care. International Journal of Clinical Psychopharmacology 2003;18(4):211-217 (Pubitemid 36871872)
13. Malt UF, Robak OH, Madsbu H-P, Bakke O, Loeb M. The Norwegian naturalistic treatment study of depression in general practice (NORDEP)- randomised double blind study. BMJ 1999;318(7192):1180-1184 (Pubitemid 29201575)
14. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 1995;310(6877):441-445
15. Philipp M, Kohnen R, Hiller KO. Hypercum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ 1999;319(7224):1534-1538
16. Thompson C, Thompson CM. The prescribing of antidepressants in General Practice. II: A placebo-controlled trial of low-dose dothiepin. Human Psychopharmacology 1989;4(3):191-204. (Pubitemid 19211780)
17. Thomson J, Rankin H, Ashcroft GW, Yates CM, McQueen JK, Cummings SW. The prescribing of antidepressants in General Practice. II: A placebo-controlled trial of low-dose dothiepin: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Pscychological Medicine 1982;12:741-751
18. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology 2002;17(3):95-102. (Pubitemid 34442189)
19. * Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993;342:837-839
20. Andersen G, Vestergaard K, Riis JO. Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences 1993;20:S115.
21. Bakish D, Wiens A, Ellis J, Alda M, Lapierre Y. A double-blind placebo-controlled comparison ofmoclobemide and amitriptyline in the treatment of depression. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 1992;37(Suppl 1):12-17
22. * Barrett JE, Williams JW Jr, Oxman TE, Katon W, Frank E, Hegel MT, Sullivan M, Schulberg HC. The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. General Hospital Psychiatry 1999;21(4):260-273.
23. Barrett JE, Williams JW Jr, Oxman TE, Frank E, Katon W, Sullivan M, Hegel MT, Cornell JE, Sengupta AS. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. Journal of Family Practice 2001;50(5):405-412 (Pubitemid 32440814)
24. Borson S, McDonald GJ, Gayle T, Deffebach M, Lakshminarayan S, VanTuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992;33(2):190-201.
25. Gomez JR, Gomez G. The treatment of anxiety and depression in general practice using an amitriptyline-perphenazine preparation. British Journal of Clinical Practice 1968;22(3):105-109
26. Houston J, Berg I, Butler A, McGuire R. Amitriptyline for depressed women with young children in general practice. British Journal of Psychiatry 1983;142:103-104 (Pubitemid 13196547)
27. Jacobs MA.Approach to studying drug effects in ambulatory patients. Archives of General Psychiatry 1965;13:163-171
28. Katz T, Fisher P, Katz A, Davidson J, Feder G. The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice. Homeopathy: the Journal of the Faculty of Homeopathy 2005;94(3):145-152 (Pubitemid 40916914)
29. Laakman G, Faltermaier Temizel M, Bossert Zaudig S, Baghai T, Lorkowski G. Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. Psychopharmacology 1995;120(1):109-115
30. Lehmann HE, Pecknold JC, Ban TA, Orbach L.A double-blind comparative clinical trial with maprotiline (Ludiomil) and imipramine in newly-admitted depressed patients. Current Therapeutic Research, Clinical and Experimental 1976;19(4):463-468
31. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. International Clinical Psychopharmacology 1998;13(2):63-73. (Pubitemid 28218516)
32. O'Hara H, O'Hara J, Valle Jones JC, McGhie RL, Brodie NH, Schiff AA. Maprotiline and fluphenazine/nortriptyline in depression. Practitioner 1978;221(1323):419-423
33. * Paykel ES, Hollyman JA, Freeling P, Sedgwick P. Predictors of therapeutic benefit from amitriptyline inmild depression: A general practice placebo-controlled trial. Journal of Affective Disorders 1988;14(1):83-95.
34. Rickels K, Gordon PE, Meckelnburg R, Sablosky L, Whalen EM, Dion H. Iprindole in neurotic depressed general practice patients: A controlled study. Psychosomatics 1968;9(4):208-214
35. Rickels K, Laquer KG, Rial WY, Rosenfeld H, Schneider B, Wagner IG. The combination of protriptyline and oxazepam in depressed neurotic general-practice patients. Psychosomatics 1971;12(5):341-348
36. Rickels K, London J, Fox I, Hassman H, Csanalosi I, Weise C. Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: a controlled study. Pharmacopsychiatry 1991;24(4):127-131
37. Schiff AA, Murphy JE, & Anderson JA. Non-pharmacological factors in drug therapy: The inter-action of doctor, patient and tablet appearance in the treatment of anxiety/depressive syndromes. Journal of International Medical Research 1975;3:125-133
38. Sussex Clinical Trials Group. Separate and combined anxiolytic and anti-depressant treatment of mixed anxiety/depression. A double-blind, placebo controlled comparison. Acta Psychiatrica Scandinavica 1985;72(1):81-88
39. Thompson C.Management of depression in real-life settings: knowledge gained from large-scale clinical trials. International Clinical Psychopharmacology 1994;9(suppl 3):21-25.
40. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995;310(6992):1433-1438
41. Anderson IM. Meta-analytical studies on new antidepressants. British Medical Bulletin 2001;57:161-178
42. American Psychiatric Association. Practice guidelines for major depressive disorder in adults. American Journal of Psychiatry 1993;150:Suppl 4.
43. Arroll B, Goodyear-Smith F, Lloyd T. Depression in patients in an Auckland General Practice. New Zealand Journal of Medicine 2002;115(1152):176- 179 (Pubitemid 36004449)
44. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I. Efficacy and tolerability of tricyclic antidepressants and SSRI compared with placebo for treatment of depression in primary care: a meta-analysis. Annals of Family Medicine 2005;3(5):449-456 (Pubitemid 41512663)
45. Arya R. The managment of depression in primary health care. Current Opinion in Psychiatry 1999;12(1):103-107 (Pubitemid 29080684)
46. Ellis PM, Smith DA. Treating depression: the beyond blue guidelines for treating depression in primary care. Medical Journal of Australia 2002;176:S77-S83.
47. Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants systematic review. BMJ 2002;325:991-1000. (Pubitemid 35305144)
48. Gill D. Prescribing antidepressants in general practice. Systematic review of all pertinent trials is required to establish guidelines. BMJ 1997;314:826-827
49. Goldberg D, Privett M, Ustun B, Simon G, Linden M. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. British Journal of General Practice 1998;48(437):1840-1844 (Pubitemid 28552140)
50. Hamilton A. A rating scale for depression. Journal of Neurology Neurosurgery and Psychiatry 1960;23(1):56-62.
51. Higgins JPT, Altman PG. editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
52. Jenkins GC. Management of patients with depression. British Journal of General Practice 2001;51(472):932-933
53. Joffe R, Sokolov S. Antidepressant treatment of depression: a meta-analysis. Canadian Journal of Psychiatry 1996;41:613-616
54. King M, Davidson O, Taylor F, Haines A, Sharp D, Turner R. Effectiveness of teaching general practitioners skills in brief cognitive behaviour therapy to treat patients with depression: randomised controlled trial. BMJ 2002;324(7343):947-950 (Pubitemid 34429875)
55. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The emperor's new drugs: an analysis of antidepressantmedication data submitted to the US Food and drug administration. Prevention and Treatment 2002;5:1522-1534
56. Kirsch I, Deacon BJ, Huedo-Medina T, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug organisation. PLOS Medicine 2008;5(2):e45. (Pubitemid 351317657)
57. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, et al.Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003;326(7397):1014-1017 (Pubitemid 36566861)
58. Magpie Research Group. The nature and prevalence of psychological problems in New Zealand primary healthcare: a report on mental health and general practice investigation (MAGPIE). New Zealand Medical Journal 2003;116:1171-1185.
59. Moher D, Cook DJ, Jadad AR, Tugwell P, Moher M, Johnes A, et al.Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technology Assessment 1999;3(12):1-98. (Pubitemid 29270516)
60. Moncrieff J, Churchill R, Drummond C, McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. International Journal of Methods in Psychiatric Research 2001;10:126-133 (Pubitemid 33014580)
61. Montgomer SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389 (Pubitemid 9136500)
62. Mulrow CD, Williams LW, Chiquette E, Aguilar C, Hitchcock-Noel P, Lee S, et al.Efficacy of newer medications for treating depression in primary care patients. American Journal of Medicine 2000;108(1):54-64. (Pubitemid 30058278)
63. National Coordinating Centre for Health Technology Assessment. Health technology briefing paper: Drug treatment of mild depression. NCCHTA, 2000.
64. Oakley-Browne MA, Wells JE, Scott KM. Te Rau Hinengaro: The New Zealand Mental Health Survey. Wellington: Ministry of Health, 2006.
65. Simon GE. Venlafaxine is more effective than selective serotonin-reuptake inhibitors for depression. ACP Journal Club 2002;137:101.
66. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al.Selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis of efficacy and acceptability. BMJ 1993;306(6879):683-687
67. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIS and TCAs: a meta-analysis. Depression and Anxiety 1997;6(1):10-18.
68. Suh T, Gallo JJ. Themanagement of depression among general medical service providers. Psychological Medicine 1999;27:1051-1063
69. Williams JW, Mulrow CD, Chiquette E, Noel PH, Acaster C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Annals of Internal Medicine 2000;132(9):743-756 (Pubitemid 30244176)